Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Docetaxel as Neoadjuvant Therapy in Early-Stage or Locally Advanced Breast Cancer

Docetaxel as Neoadjuvant Therapy in Early-Stage or Locally Advanced Breast Cancer Am J Cancer 2006; 5 (3): 207-209 GUEST COMMENTARIES 1175-6357/06/0003-0207/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. increased axillary lymph node pCR, which is also associated with Docetaxel as Neoadjuvant Therapy in Early- important prognostic information, and an increase in the rate of Stage or Locally Advanced Breast Cancer breast conserving surgery in the taxane-containing study arms. A Viewpoint by Steven D. Heys and Nicole J. McCarthy Despite these well conducted randomized trials, the optimal schedule and number of cycles of docetaxel needed remains elu- 1 Department of Surgical Oncology, University of Aberdeen, sive. The combination studies use docetaxel 75 mg/m while the Aberdeen, Scotland sequential studies use 100 mg/m . There is one comparative trial 2 Division of Medical Oncology, Royal Brisbane and Women’s Hospital, Brisbane, Australia that shows six cycles of neoadjuvant docetaxel is better than three, and it remains unknown if four could be the optimal number. Neoadjuvant chemotherapy now represents the standard of care The most important issue remaining is the impact of taxanes on for women with locally advanced breast cancer. Increasingly, survival in the neoadjuvant setting. Although disease-free and neoadjuvant chemotherapy has been used to downstage larger, overall survival benefits have http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Docetaxel as Neoadjuvant Therapy in Early-Stage or Locally Advanced Breast Cancer

American Journal of Cancer , Volume 5 (3) – Aug 10, 2012

Docetaxel as Neoadjuvant Therapy in Early-Stage or Locally Advanced Breast Cancer

Abstract

Am J Cancer 2006; 5 (3): 207-209 GUEST COMMENTARIES 1175-6357/06/0003-0207/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. increased axillary lymph node pCR, which is also associated with Docetaxel as Neoadjuvant Therapy in Early- important prognostic information, and an increase in the rate of Stage or Locally Advanced Breast Cancer breast conserving surgery in the taxane-containing study arms. A Viewpoint by Steven D. Heys and Nicole J. McCarthy Despite these well...
Loading next page...
 
/lp/springer-journals/docetaxel-as-neoadjuvant-therapy-in-early-stage-or-locally-advanced-ct0JzKfaAY
Publisher
Springer Journals
Copyright
Copyright © 2006 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200605030-00008
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2006; 5 (3): 207-209 GUEST COMMENTARIES 1175-6357/06/0003-0207/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. increased axillary lymph node pCR, which is also associated with Docetaxel as Neoadjuvant Therapy in Early- important prognostic information, and an increase in the rate of Stage or Locally Advanced Breast Cancer breast conserving surgery in the taxane-containing study arms. A Viewpoint by Steven D. Heys and Nicole J. McCarthy Despite these well conducted randomized trials, the optimal schedule and number of cycles of docetaxel needed remains elu- 1 Department of Surgical Oncology, University of Aberdeen, sive. The combination studies use docetaxel 75 mg/m while the Aberdeen, Scotland sequential studies use 100 mg/m . There is one comparative trial 2 Division of Medical Oncology, Royal Brisbane and Women’s Hospital, Brisbane, Australia that shows six cycles of neoadjuvant docetaxel is better than three, and it remains unknown if four could be the optimal number. Neoadjuvant chemotherapy now represents the standard of care The most important issue remaining is the impact of taxanes on for women with locally advanced breast cancer. Increasingly, survival in the neoadjuvant setting. Although disease-free and neoadjuvant chemotherapy has been used to downstage larger, overall survival benefits have

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

There are no references for this article.